Co-delivery system of chemotherapy drugs and active ingredients from natural plants: a brief overview of preclinical research for cancer treatment

Guo, Pu; He, Yingmeng; Xu, Ting; Pi, Chao; Jiang, Qingsheng; Wei, Yumeng; Zhao, Ling

doi:10.1080/17425247.2020.1739647

Cited by 12 publications

(10 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liposomes, niosomes, lipid micelles, nano-emulsions, solid lipid nanoparticles, polymeric nanoparticles, chitosan-based nanoparticles, and nanostructured lipid carriers are all examples of lipid-based nanocarriers [ 14 , 64 , 65 ]. However, the most eminent and significant lipid-based nanocarriers for efficient co-delivery are liposomes and nano-emulsions [ 14 , 66 ].…”

Section: Nanocarriers Used In Co-delivery Systemsmentioning

confidence: 99%

“…Drug release can be triggered by external and/or internal mechanisms such as ultrasound, heat, enzymes, pH, etc. AlSawaftah et al established that ultrasound, at a specific intensity and frequency, induces transient pores, also known as sonoporation, which enhances drug release from the liposomes and drug uptake in cancer cells [ 66 ] ( Figure 2 ).…”

Section: Nanocarriers Used In Co-delivery Systemsmentioning

confidence: 99%

See 1 more Smart Citation

Recent Advances in Nanoparticle-Based Co-Delivery Systems for Cancer Therapy

2022

View full text Add to dashboard Cite

Cancer therapies have advanced tremendously throughout the last decade, yet multiple factors still hinder the success of the different cancer therapeutics. The traditional therapeutic approach has been proven insufficient and lacking in the suppression of tumor growth. The simultaneous delivery of multiple small-molecule chemotherapeutic drugs and genes improves the effectiveness of each treatment, thus optimizing efficacy and improving synergistic effects. Nanomedicines integrating inorganic, lipid, and polymeric-based nanoparticles have been designed to regulate the spatiotemporal release of the encapsulated drugs. Multidrug-loaded nanocarriers are a potential strategy to fight cancer and the incorporation of co-delivery systems as a feasible treatment method has projected synergistic benefits and limited undesirable effects. Moreover, the development of co-delivery systems for maximum therapeutic impact necessitates better knowledge of the appropriate therapeutic agent ratio as well as the inherent heterogeneity of the cancer cells. Co-delivery systems can simplify clinical processes and increase patient quality of life, even though such systems are more difficult to prepare than single drug delivery systems. This review highlights the progress attained in the development and design of nano carrier-based co-delivery systems and discusses the limitations, challenges, and future perspectives in the design and fabrication of co-delivery systems.

show abstract

Section: Nanocarriers Used In Co-delivery Systemsmentioning

confidence: 99%

Section: Nanocarriers Used In Co-delivery Systemsmentioning

confidence: 99%

Recent Advances in Nanoparticle-Based Co-Delivery Systems for Cancer Therapy

2022

View full text Add to dashboard Cite

show abstract

“…Co-delivery systems for drug delivery come in many designs. They may comprise carriers, where one or more drugs are packaged into liposomes, nanoparticles, hydrogels, dendrimers, or other vehicles [119,120], and some of these are being developed specifically for the purpose of intranasal delivery to reach the brain via the nose-to-brain route [121,122]. Studies with POH have also revealed characteristics that make this monoterpenoid suitable for the purpose of transporting other drugs directly to the brain via the nose-to-brain route.…”

Section: Intranasal Poh As a Co-delivery Systemmentioning

confidence: 99%

The Monoterpenoid Perillyl Alcohol: Anticancer Agent and Medium to Overcome Biological Barriers

et al. 2021

View full text Add to dashboard Cite

Perillyl alcohol (POH) is a naturally occurring monoterpenoid related to limonene that is present in the essential oils of various plants. It has diverse applications and can be found in household items, including foods, cosmetics, and cleaning supplies. Over the past three decades, it has also been investigated for its potential anticancer activity. Clinical trials with an oral POH formulation administered to cancer patients failed to realize therapeutic expectations, although an intra-nasal POH formulation yielded encouraging results in malignant glioma patients. Based on its amphipathic nature, POH revealed the ability to overcome biological barriers, primarily the blood–brain barrier (BBB), but also the cytoplasmic membrane and the skin, which appear to be characteristics that critically contribute to POH’s value for drug development and delivery. In this review, we present the physicochemical properties of POH that underlie its ability to overcome the obstacles placed by different types of biological barriers and consequently shape its multifaceted promise for cancer therapy and applications in drug development. We summarized and appraised the great variety of preclinical and clinical studies that investigated the use of POH for intranasal delivery and nose-to-brain drug transport, its intra-arterial delivery for BBB opening, and its permeation-enhancing function in hybrid molecules, where POH is combined with or conjugated to other therapeutic pharmacologic agents, yielding new chemical entities with novel mechanisms of action and applications.

show abstract

“…Recent studies have found that PTX in combination with natural drug monomers, such as curcumin (CU), triptolide, and honokiol, can reduce the dose of PTX needed and increase the therapeutic effect (Liu et al, 2018 ; Guo et al, 2020 ; Li et al, 2021 ). Furthermore, numerous preclinical studies have shown that a combination of PTX and CU may be an effective strategy to synergistically improve the therapeutic efficacy of cancer therapeutics and reverse multidrug resistance (MDR) (Calaf et al, 2018 ; Ashrafizadeh et al, 2020 ; Lee et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Anti-lung cancer effect of paclitaxel solid lipid nanoparticles delivery system with curcumin as co-loading partner in vitro and in vivo

Zhao

Zeng

et al. 2022

Drug Delivery

Self Cite

View full text Add to dashboard Cite

The main aim of this study was to improve the therapeutic potential of a paclitaxel (PTX) and curcumin (CU) combination regimen using solid lipid nanoparticles (SLNs). PTX and CU were successfully co-encapsulated at a predetermined ratio in SLNs (PC-SLNs) with high encapsulation efficiency (CU: 97.6%, PTX: 95.8%), appropriate particle size (121.8 ± 1.69 nm), small PDI (0.267 ± 0.023), and negative zeta potential (–30.4 ± 1.25 mV). Compared with PTX or the combination of CU and PTX (CU + PTX), PC-SLNs can greatly reduce the dose of PTX while still achieving the same therapeutic effect on four cancer cell lines, among which the inhibitory effect on A549 lung cancer cells was the strongest. PC-SLNs improved the area under the curve (CU: 1.40-fold; PTX: 2.88-fold), prolonged the residence time (CU: 6.94-fold; PTX: 2.51-fold), and increased the half-life (CU: 5.62-fold; PTX: 6.46-fold), achieving long circulation. PC-SLNs were used to treat lung cancer in a nude mouse xenograft tumor model and the tumor suppression rate reached 78.42%, while those of PTX and (CU + PTX) were 40.53% and 51.56%, respectively. As PC-SLNs can prevent P-glycoprotein efflux, reverse MDR and downregulate the NF-κB pathway. PC-SLNs are a potential antineoplastic agent that is more effective and less toxic in treating lung cancer.

show abstract

Co-delivery system of chemotherapy drugs and active ingredients from natural plants: a brief overview of preclinical research for cancer treatment

Cited by 12 publications

References 85 publications

Recent Advances in Nanoparticle-Based Co-Delivery Systems for Cancer Therapy

Recent Advances in Nanoparticle-Based Co-Delivery Systems for Cancer Therapy

The Monoterpenoid Perillyl Alcohol: Anticancer Agent and Medium to Overcome Biological Barriers

Anti-lung cancer effect of paclitaxel solid lipid nanoparticles delivery system with curcumin as co-loading partner in vitro and in vivo

Contact Info

Product

Resources

About